Nabla Bio is a biotechnology company specializing in the de novo design of antibody therapeutics through the integration of artificial intelligence (AI) and experimental technologies. Founded by experts from George Church's Lab at Harvard, Nabla Bio combines generative AI models with large-scale multiplex experiments to engineer protein-based therapies, particularly targeting applications where traditional discovery methods have been less effective.